Anshul Mangal

Recent headlines suggest that the biotech industry as a whole is experiencing a downturn, yet in spite of this narrative the momentum for advanced therapies continues to persevere. Many companies in the cell and gene therapy space are dedicated to bringing these novel therapies to the patients who need them. Researchers are diligently creating new methods for cell and gene editing as well as therapeutic delivery to increase safety, accessibility, and affordability.

The cell and gene therapy industry has experienced exponential growth in the last three years and as funding for the field continues to break records there are no signs of a slowdown. With 2,261 ongoing clinical trials in regenerative medicine, the FDA expects to approve1 between 10 and 20 new cell and gene therapies a year by 2025. Gene editing and CRISPR technologies are also quickly advancing with many companies heading to the clinic in the next few years. The need for solutions to the… Show more

The cell and gene therapy industry has experienced exponential growth in the last three years and as funding for the field continues to break records there are no signs of a slowdown. With 2,261 ongoing clinical trials in regenerative medicine, the FDA expects to approve1 between 10 and 20 new cell and gene therapies a year by 2025. Gene editing and CRISPR technologies are also quickly advancing with many companies heading to the clinic in the next few years. The need for solutions to the industry’s biggest bottlenecks are growing daily. Show less

In recent years the advanced therapy industry has been the most significant disruptor in medicine. Cell and gene therapies are transforming the way diseases are treated but are also aiming to cure entirely new patient populations. New applications and indications are being researched daily with the hope to address an array of rare and chronic diseases that have long been thought incurable. As researchers and developers work to transform the way we treat diseases, cell and gene therapies will… Show more

In recent years the advanced therapy industry has been the most significant disruptor in medicine. Cell and gene therapies are transforming the way diseases are treated but are also aiming to cure entirely new patient populations. New applications and indications are being researched daily with the hope to address an array of rare and chronic diseases that have long been thought incurable. As researchers and developers work to transform the way we treat diseases, cell and gene therapies will continue to be the center of innovation in the coming years. Show less

The commercialization of cell and gene therapies raises several complex conversations and questions for employers and payers. Without proper solutions and partnerships, employers and health insurers will be held responsible for extreme medical costs associated with gene therapy. Despite the many challenges of the last two years, the global cell and gene therapy (CGT) market continues to rapidly expand. The investment landscape for regenerative medicine has grown 16% in 3 years, hitting an… Show more

The commercialization of cell and gene therapies raises several complex conversations and questions for employers and payers. Without proper solutions and partnerships, employers and health insurers will be held responsible for extreme medical costs associated with gene therapy. Despite the many challenges of the last two years, the global cell and gene therapy (CGT) market continues to rapidly expand. The investment landscape for regenerative medicine has grown 16% in 3 years, hitting an all-time high in 2021 of $23.1 billion raised. With more funding pouring in each year and over 2,261 ongoing global clinical trials in regenerative medicine, the market is expected to reach $34.31 billion in 2030. With this immense growth potential, the industry is reaching a tipping point heading towards commercialization. Cell and gene therapies provide hope for many patients suffering from rare diseases, creating great urgency to bring these treatments to market.

The commercialization of CGTs forces several complex economical conversations and questions, some concerns include manufacturing, labor challenges, payer coverage, adequate reimbursement, and cost-effectiveness. To find adequate solutions, we must first have a deep understanding of the process and factors driving the high-ticket price of these life-saving therapies. Show less